Dermata Therapeutics, Inc.
3525 Del Mar Heights, Road, #322
San Diego, CA 92130
Tel: (858) 800-2543
November
22, 2022
VIA EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, N.E.
Re:
Dermata
Therapeutics, Inc.
Registration
Statement on Form S-3 (File No. 333-268383)
Filed
on November 15, 2022
Ladies
and Gentlemen:
Dermata
Therapeutics, Inc. (the “Registrant”) hereby
requests that the U.S. Securities and Exchange Commission (the
“Commission”) take appropriate action to cause the
above-referenced Registration Statement on Form S-3 to become
effective on November 25, 2022, at 5:00 p.m., Eastern Time, or as
soon thereafter as is practicable or at such later time as the
Registrant, or its representative, may orally request via telephone
call to the staff of the Commission.
Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947
to confirm the effectiveness of the Registration Statement or with
any questions.
Very
truly yours,
DERAMTA
THERAPEUTICS, INC.
By:
/s/ Gerald T.
Proehl
Name:
Gerald T. Proehl
Title:
Chief Executive Officer